Bangkok – Roche Diagnostics (Thailand) Co., Ltd. is pleased to announce the appointment of Mr. Mihai Irimescu as the company's new General Manager. Mr. Irimescu will lead the charge in strengthening our company’s success in & commitment to the Thai market and contributing to our growth in the Asia Pacific region. His tenure officially begins on February 1, 2024, based at the company headquarters in Bangkok.

With a robust background in the pharmaceutical industry spanning over 13 years, Mr. Irimescu brings a wealth of experience to his new role. He joined Roche in 2019 as the Director of Roche Diabetes Care Sub-Region Asia Frontier Markets, based in Singapore. Subsequently, he was appointed as the Head of Asia Emerging Markets Cluster at Roche Diabetes Care in January 2020, based in Thailand, from where he oversaw sustained growth and geographical expansion of our Diabetes Care business in fourteen markets. His appointment as the General Manager underscores his proven track record and leadership within the organization.

In his previous roles, Mr. Irimescu has demonstrated his expertise and professionalism in various capacities. Notably, he served as Vice President & General Manager of Thailand and Head of Strategic Pricing, Global Market Access at Novo Nordisk, based in Copenhagen, Denmark. His diverse background encompasses global, regional, and local market experience, making him well-equipped to drive Roche Diagnostics Thailand's sustainable success in the healthcare industry.

Reflecting on his new position, Mr. Irimescu expressed his commitment to positioning Roche Diagnostics (Thailand) as a trusted partner in the healthcare industry ecosystem. He emphasized the importance of improving access to diagnostic testing, therefore contributing to a sustainable healthcare system as well as to enhancing the quality of life of Thai people.

Mr. Irimescu holds a Master of Science in Management from BI Norwegian School of Management and has previously worked in the telecom and IT industries.


About Roche Diagnostics (Thailand) Co., Ltd.
Roche Diagnostics (Thailand) Co., Ltd. is a leading provider of innovative diagnostic solutions, committed to improving healthcare outcomes for patients in Thailand and beyond. With a focus on personalized healthcare, Roche Diagnostics (Thailand) strives to empower healthcare professionals with cutting-edge technologies and insights.


About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.


This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid